Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.62 |
| ▸ | PIK3R1 | P27986 | 14/20 | 0.62 |
| ▸ | MTOR | P42345 | 8/20 | 0.62 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.44 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.44 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.44 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311059 | 0.90 | PIK3CA (0.70) | PIK3CAPIK3R1MTORPARP1BRAF | |
| SCHEMBL2440200 | 0.84 | PIK3CA (0.62) | PIK3CAPIK3R1MTORPARP1BRAF | |
| SCHEMBL30819019 | 0.82 | JAK3 (0.44) | PIK3CAPIK3R1 | |
| SCHEMBL2442030 | 0.81 | PIK3CA (0.74) | PIK3CAPIK3R1MTORRICTORRPTOR | |
| SCHEMBL2472760 | 0.81 | PIK3CA (0.78) | PIK3CAPIK3R1MTORRICTORRPTOR | |
| SCHEMBL1308957 | 0.79 | PIK3CA (1.00) | PIK3CAPIK3R1MTORRICTORRPTOR | |
| SCHEMBL1309769 | 0.78 | PIK3CA (0.75) | PIK3CAPIK3R1MTORRICTORRPTOR | |
| SCHEMBL909555 | 0.76 | PIK3CA (0.69) | PIK3CAPIK3R1MTORPARP1BRAF | |
| SCHEMBL18117962 | 0.74 | PIK3CA (0.89) | PIK3CAPIK3R1MTORRICTORRPTOR | |
| SCHEMBL1308493 | 0.74 | PIK3CA (0.89) | PIK3CAPIK3R1MTORRICTORRPTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040934-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2013-02-14 | — | — | US | claimed |
| EP-2547684-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | University of Basel (CH) | 2013-01-23 | — | — | EP | claimed |
| WO-2011114275-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-09-22 | — | — | WO | claimed |
| US-20130040934-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2013-02-14 | — | — | US | disclosed |
| EP-2547684-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | University of Basel (CH) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011114275-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040934-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | CDK4, GRK4, RPS6KA4 | PIK3CA 13/4885PIK3R1 151/4885MTOR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.